Exact Sciences Corporation (NASDAQ:EXAS) CEO Kevin T. Conroy sold 137,805 shares of Exact Sciences Corporation stock in a transaction that occurred on Thursday, November 9th. The stock was sold at an average price of $59.14, for a total transaction of $8,149,787.70. Following the sale, the chief executive officer now owns 967,867 shares of the company’s stock, valued at approximately $57,239,654.38. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Shares of Exact Sciences Corporation (NASDAQ:EXAS) traded up $1.19 on Monday, reaching $60.37. 1,352,200 shares of the company’s stock were exchanged, compared to its average volume of 2,562,707. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.98 and a current ratio of 10.34. Exact Sciences Corporation has a 1 year low of $13.05 and a 1 year high of $63.60.

Exact Sciences Corporation (NASDAQ:EXAS) last announced its quarterly earnings results on Monday, October 30th. The medical research company reported ($0.23) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.07. Exact Sciences Corporation had a negative net margin of 60.71% and a negative return on equity of 30.32%. The firm had revenue of $72.60 million for the quarter, compared to analyst estimates of $65.03 million. During the same quarter in the previous year, the firm posted ($0.36) earnings per share. The business’s revenue was up 158.4% on a year-over-year basis. analysts anticipate that Exact Sciences Corporation will post -1.14 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Exact Sciences Corporation (EXAS) CEO Sells $8,149,787.70 in Stock” was originally reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.watchlistnews.com/exact-sciences-corporation-exas-ceo-sells-8149787-70-in-stock/1700730.html.

Several brokerages have recently commented on EXAS. Leerink Swann reiterated an “outperform” rating and set a $67.00 price target (up previously from $63.00) on shares of Exact Sciences Corporation in a research report on Monday. Robert W. Baird cut shares of Exact Sciences Corporation from an “outperform” rating to a “neutral” rating and set a $56.00 price target for the company. in a research report on Monday. Zacks Investment Research cut shares of Exact Sciences Corporation from a “buy” rating to a “hold” rating in a research report on Thursday, November 2nd. BTIG Research lowered shares of Exact Sciences Corporation from a “buy” rating to a “neutral” rating in a research note on Wednesday, November 1st. Finally, Bank of America Corporation lifted their price objective on shares of Exact Sciences Corporation from $56.00 to $58.00 and gave the stock a “buy” rating in a research note on Tuesday, October 31st. Eight analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Exact Sciences Corporation currently has a consensus rating of “Buy” and a consensus target price of $49.98.

Several hedge funds have recently made changes to their positions in EXAS. Prudential Financial Inc. lifted its position in shares of Exact Sciences Corporation by 3.0% in the first quarter. Prudential Financial Inc. now owns 11,141 shares of the medical research company’s stock worth $263,000 after purchasing an additional 320 shares in the last quarter. Teachers Advisors LLC lifted its position in shares of Exact Sciences Corporation by 4.7% in the first quarter. Teachers Advisors LLC now owns 183,485 shares of the medical research company’s stock worth $4,334,000 after purchasing an additional 8,221 shares in the last quarter. Renaissance Technologies LLC bought a new stake in shares of Exact Sciences Corporation in the first quarter worth $8,298,000. BlackRock Inc. lifted its position in shares of Exact Sciences Corporation by 45,816.0% in the first quarter. BlackRock Inc. now owns 6,804,297 shares of the medical research company’s stock worth $160,718,000 after purchasing an additional 6,789,478 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. lifted its position in shares of Exact Sciences Corporation by 15.7% in the first quarter. Schwab Charles Investment Management Inc. now owns 483,849 shares of the medical research company’s stock worth $11,429,000 after purchasing an additional 65,619 shares in the last quarter. 85.65% of the stock is currently owned by institutional investors and hedge funds.

Exact Sciences Corporation Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Insider Buying and Selling by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.